Compounds with glucocorticoid sparing effects and uses thereof
AssigneeThe Regents of the University of California
InventorsDennis A. Carson, Tomoko Hayashi, Mary Patricia Corr, Howard B. cottam, Tadashi Hosoya, Nikunj Shukla
Life of this patent
Estimating the term…
Abstract
The disclosure relates to 1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds and 1-nitro-5-amido-disubstituted furan compounds, or a pharmaceutically acceptable salt thereof, and methods for their use in treating, among other conditions, inflammatory diseases or an autoimmune diseases.
Claims30
A compound of the formula (I):
- or pharmaceutically acceptable salt thereof,
- wherein:
- R1 is aryl or heterocyclyl;
- R2 is alkyl or cycloalkyl, wherein the cycloalkyl is not amino- or amido-substituted when R1 is aryl;
- R3 and R4 are each independently H or alkyl;
- and
- the compound is not a compound of the formula:
3-4. (canceled)
(canceled)
8-12. (canceled)
A compound of the formula (II):
- or pharmaceutically acceptable salt thereof,
- wherein:
- R5 is H, alkyl or OR7, wherein R7 is H or alkyl;
- and
- R6 is aryl, monocyclic pyrrolidinyl or pyrrolyl;
- bicyclic furany;
- thiophenyl;
- indolyl, and benzimidazolyl;
- wherein R5 is alkyl or OR7 when R6 is aryl, thiopehnyl, indolyl or benzimidazolyl.
(canceled)
A method for reducing at least one of NF-κB activity and chemokine secretion induced by immunologic stimuli, the method comprising administering at least one of a 1H-pyrazolo[3,4-cl]pyrimidin-4-amine compound and an 1-nitro-5-amido-disubstituted furan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
(canceled)
24-25. (canceled)
(canceled)
29-31. (canceled)
(canceled)
A method for:
- (i) treating an inflammatory disease or an autoimmune disease comprising administering a therapeutically effective amount of at least one of a 1H-pyrazolo [3, 4-d]pyrimidin-4-amine compound and a 1-nitro-5-amido-disubstituted furan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof;
- or (ii) for treating nociceptive pain or allodynia comprising administering a therapeutically effective amount of a 1-nitro-5-amido-disubstitued furan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
(canceled)
Dependencies are inferred from the claim text.